Analysts Offer Predictions for CRBP FY2029 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – HC Wainwright issued their FY2029 earnings per share estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects that the biopharmaceutical company will earn ($3.56) per share for the year. HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share.

CRBP has been the topic of a number of other research reports. StockNews.com raised shares of Corbus Pharmaceuticals to a “sell” rating in a research note on Monday, January 13th. Wedbush reiterated an “outperform” rating and issued a $51.00 target price on shares of Corbus Pharmaceuticals in a research report on Monday, November 4th. Finally, Piper Sandler started coverage on shares of Corbus Pharmaceuticals in a research report on Monday, December 2nd. They set an “overweight” rating and a $35.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.38.

Corbus Pharmaceuticals Stock Performance

Corbus Pharmaceuticals stock opened at $8.78 on Wednesday. The business has a 50 day simple moving average of $12.49 and a 200-day simple moving average of $26.68. Corbus Pharmaceuticals has a 12 month low of $8.74 and a 12 month high of $61.90.

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of CRBP. Charles Schwab Investment Management Inc. lifted its stake in Corbus Pharmaceuticals by 4.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 97,882 shares of the biopharmaceutical company’s stock worth $1,155,000 after purchasing an additional 4,239 shares in the last quarter. HealthInvest Partners AB increased its holdings in shares of Corbus Pharmaceuticals by 41.3% in the fourth quarter. HealthInvest Partners AB now owns 98,304 shares of the biopharmaceutical company’s stock valued at $1,188,000 after purchasing an additional 28,731 shares during the last quarter. Avanza Fonder AB purchased a new position in Corbus Pharmaceuticals during the fourth quarter worth approximately $84,000. JPMorgan Chase & Co. boosted its stake in Corbus Pharmaceuticals by 27.0% during the third quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,172 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Corbus Pharmaceuticals by 8.1% during the third quarter. Geode Capital Management LLC now owns 249,759 shares of the biopharmaceutical company’s stock worth $5,154,000 after buying an additional 18,702 shares during the last quarter. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.